EGF anticorps (AA 847-876)

N° du produit ABIN5532554

Détail du produit anti-EGF anticorps

Antigène: EGF (Epidermal Growth Factor (EGF))

Épitope: AA 847-876

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EGF est non-conjugé

Application: Western Blotting (WB)

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This EGFR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 847-876 amino acids from human EGFR.

Isotype: Ig Fraction

Information d'application

Indications d'application: For WB starting dilution is: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.3 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur EGF

Antigène: EGF (Epidermal Growth Factor (EGF))

Autre désignation: EGF (EGF Produits)

Synonymes: anticorps HOMG4, anticorps URG, anticorps AI790464, anticorps CEGF, anticorps epidermal growth factor, anticorps pro-epidermal growth factor, anticorps EGF, anticorps egf, anticorps CpipJ_CPIJ020278, anticorps Egf

Sujet: EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Poids moléculaire: 134 kDa

ID gène: 1956

UniProt: P00533

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation